- Home
- LPTX vs IMNN Comparison
LPTX vs IMNN Comparison
Compare LPTX & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- IMNN
- Stock Information
- Founded
- LPTX 2011
- IMNN 1982
- Country
- LPTX United States
- IMNN United States
- Employees
- LPTX N/A
- IMNN N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- LPTX Health Care
- IMNN Health Care
- Exchange
- LPTX Nasdaq
- IMNN Nasdaq
- Market Cap
- LPTX 14.7M
- IMNN 12.1M
- IPO Year
- LPTX N/A
- IMNN 1985
- Fundamental
- Price
- LPTX $0.31
- IMNN $7.08
- Analyst Decision
- LPTX Hold
- IMNN Buy
- Analyst Count
- LPTX 1
- IMNN 2
- Target Price
- LPTX N/A
- IMNN $210.00
- AVG Volume (30 Days)
- LPTX 661.1K
- IMNN 500.6K
- Earning Date
- LPTX 08-19-2025
- IMNN 08-05-2025
- Dividend Yield
- LPTX N/A
- IMNN N/A
- EPS Growth
- LPTX N/A
- IMNN N/A
- EPS
- LPTX N/A
- IMNN N/A
- Revenue
- LPTX N/A
- IMNN N/A
- Revenue This Year
- LPTX N/A
- IMNN N/A
- Revenue Next Year
- LPTX N/A
- IMNN N/A
- P/E Ratio
- LPTX N/A
- IMNN N/A
- Revenue Growth
- LPTX N/A
- IMNN N/A
- 52 Week Low
- LPTX $0.22
- IMNN $4.83
- 52 Week High
- LPTX $4.79
- IMNN $41.22
- Technical
- Relative Strength Index (RSI)
- LPTX 43.86
- IMNN 42.63
- Support Level
- LPTX $0.30
- IMNN $6.45
- Resistance Level
- LPTX $0.37
- IMNN $8.19
- Average True Range (ATR)
- LPTX 0.03
- IMNN 0.83
- MACD
- LPTX -0.00
- IMNN 0.30
- Stochastic Oscillator
- LPTX 28.53
- IMNN 56.08
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).